Rein Therapeutics, Inc. (RNTX) Free cash flow 2016–2022
Rein Therapeutics, Inc. (RNTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$25.0MFY2022 · since FY2016: -$15.1M → -$25.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -$25.0M | -5.3% |
| FY2021 | -$23.8M | -15.2% |
| FY2020 | -$20.6M | +33.2% |
| FY2019 | -$30.9M | -10.1% |
| FY2018 | -$28.1M | — |
| FY2016 | -$15.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net incomeRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating incomeRNTX Operating marginRNTX Operating cash flowRNTX Capital expendituresRNTX Return on equityRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Total liabilitiesRNTX Shareholders’ equityRNTX overview →